U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...

Reports

2

Domains carrying it

2

First reported

19 August 2026

Latest report

20 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 19 August 2026U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...ir.tevapharm.com
2. 20 August 2026Teva's first-in-class Tourette drug filed for approval with FDA priority statusallsci.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Teva moves closer to a drug for celiac disease with positive Phase 2 results3 reports · 3 domains · 3 September 2026
• FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage ...4 reports · 4 domains · 1 September 2026
• Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's ...8 reports · 6 domains · 26 August 2026
• Lilly, with new data, to seek FDA approval of obesity drug retatrutide3 reports · 3 domains · 4 August 2026
• Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...2 reports · 2 domains · 1 September 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• Teva's first-in-class Tourette drug filed for approval with FDA priority statusallsci.com · 20 August 2026
• U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...ir.tevapharm.com · 19 August 2026